BioCentury
ARTICLE | Company News

Acambis, Antigenics deal

January 7, 2008 8:00 AM UTC

Acambis exercised an option to receive a non-exclusive license to use Antigenics' QS-21 Stimulon vaccine adjuvant in combination with Acambis' ACAM-FLU-A vaccine. Antigenics is eligible for undisclo...